Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses whether a product recommended by a Portuguese pharmacist is the same as Minoxidil. Treatments mentioned include Minoxidil, Finasteride, and RU58841.

The conversation is about someone's progress with hair loss treatment using Minoxidil, Finasteride, Ketoconazole, and oils. They shared progress pictures to show the results.

The user experienced progress in hair recovery using oral finasteride and minoxidil, despite some side effects like increased heart rate. They switched from foam to oral treatments for convenience and reported minimal shedding.

The conversation discusses skepticism about group buys for hair loss treatments, highlighting issues with unverified chemicals and the risks involved. It suggests stabilizing with dutasteride and minoxidil, and considering a hair transplant instead of experimenting with untested products.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

A 20-year-old experiencing hair thinning is considering treatments like minoxidil, finasteride, and various oils but is hesitant due to potential side effects. Users advise starting minoxidil and finasteride for effective results, while oils and supplements are seen as less effective.

A 23-year-old is experiencing hair loss and has been using 5% topical minoxidil, 1 mg oral finasteride, and recently switched to 1.25 mg oral minoxidil. They are hopeful for regrowth with this new regimen, which includes biotin, iron, vitamins, Nioxin shampoo, and rosemary serum.

The conversation discusses switching from topical to oral minoxidil from Healing Pharma, with concerns about the brand's legitimacy. A user reported hair regrowth using a lower dosage of oral minoxidil and finasteride from the same company.

The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.

The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.